Navigation Links
3 postulates to help identify the cause of Alzheimer's disease
Date:6/20/2011

Amsterdam, The Netherlands, June 20, 2011 -- After more than 100 years following its pathologic description, the cause of Alzheimer's disease (AD) remains unknown. To test the validity of present and future proposals related to the probable cause of AD, three postulates, or necessary conditions, are recommended by Jack de la Torre, MD, PhD, Adjunct Professor of Psychology at the University of Texas, Austin, in an article published in the Journal of Alzheimer's Disease.

"Knowing what causes AD is critically important because it would allow more effective therapy to specifically prevent new cases and apply interventions to slow down the mental decline in people who already have this dementia," commented Dr. de la Torre. "In search of the Alzheimer cause, a considerable number of hypothetical proposals have been published, but no proposal so far has reached a consensus of agreement by experts in the field. Proposals regarded as weak and insubstantial by evidence-based medicine not only cost lots of money and effort, they also hinder clinical progress."

Dr. de la Torre believes that any likely cause of AD would need to satisfy the criteria established by the three postulates when hypothetical proposals are submitted to explain the pathogenesis of AD. The first postulate requires that the cause of AD precedes the cognitive decline and neurodegenerative pathology that characterize AD. This rule identifies a primary event from a neuropathological effect generated by the disease process. The second postulate stipulates that interventions aimed at the proposed causal event should prevent or reverse the cognitive and neurodegenerative pathology associated with AD prior to disease onset. This postulate emphasizes prevention or reversal of emerging neurocognitive pathology considerably before AD onset. If the first and second postulate requirements are met, the third postulate follows that interventions targeting the causal event should significantly lower the incidence of AD.

To evaluate the potential usefulness of the three postulates, Dr. de la Torre examined seven mainstream proposals offered as the cause of AD and explored their relative merit or lack of merit on Alzheimer patients. Proposals included the amyloid-β, cell cycle, cholinergic, inflammatory, oxidative stress, tau, and vascular hypotheses.

Dr. de la Torre analyzed evidence of efficacy for each proposal obtained from high-quality clinical trials, then assessed whether such evidence met the requirements posed by each postulate. Only two of the seven proposals examined, the vascular hypothesis and the oxidative stress hypothesis, partially met the requirements of one or two but not all three postulates.

Dr. de la Torre concludes that "By questioning or helping validate a proposed cause-effect relationship to AD, the three postulates I have described may serve as a primary instrument in targeting efficient therapeutic initiatives designed to prevent, reverse, or slow down the likely cause of this dementia."


'/>"/>

Contact: Daphne Watrin
d.watrin@iospress.nl
31-206-883-355
IOS Press
Source:Eurekalert

Related medicine news :

1. UNT Health Science Centers Roby Helps Identify Bodies of Chiles Patio 29
2. Scientists identify microRNA as possible cause of chemotherapy resistance
3. University of Michigan scientists identify chemical in bananas as potent inhibitor of HIV infection
4. Study to Identify Infants at High Risk for Developing Obesity
5. Mount Sinai researchers are the first to identify heart abnormalities in World Trade Center workers
6. Researchers Identify 2 Genes Linked to Fatty Liver Disease
7. Researchers identify potential new target for treating hepatitis C
8. Researchers discover new approach for identifying smokers at highest risk for developing lung cancer
9. Researchers identify a new breast and ovarian cancer susceptibility gene
10. Blood test may identify lung cancer patients likely to respond to erlotinib
11. Genome breakthrough allows scientists to identify and profile tumor cells from very small samples
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... Fairfax, VA (PRWEB) , ... April 28, 2017 , ... ... elected volunteer board members and officers for 2017-2018. The annual board election process has ... serving on a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood Bank (TCBB), a program ... delivery team at Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in ... and decide to donate. , “Women’s Hospital at Renaissance has been a collection ...
(Date:4/28/2017)... ... 2017 , ... People are starting to accept that hearing aids can be ... the stigma it had when great-grandpa wore his hearing aids years ago,” said Dr. ... North American Speaker Series (NASS) segment. “He probably wore an iPod-size hearing ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in ... activity and sleep monitoring solutions for the global scientific community. The company’s new ...
(Date:4/28/2017)... ... April 28, 2017 , ... Woolsy Corporation Limited, ... through its Nova Skin Sciences division, recently announced the launch of Allumière Antiaging ... the power of an anti-aging concentrate. , Anogeissus Leiocarpa Bark Extract ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017 The Mobile X-Ray product segment is ... CAGR during the forecast period Mobile X-Ray segment ... digital mobile X-Ray devices market, which is estimated to be ... at a CAGR of 7% over the forecast period. Mobile ... more than US$ 100 Mn in 2017 over 2016. The ...
(Date:4/19/2017)... 19, 2017 The Global Effective Microorganisms ... 2022 report has covered and analysed the potential of Global ... market size, shares and growth factors. The report identifies and ... opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, ...
(Date:4/19/2017)... THOUSAND OAKS, Calif. , April 19, 2017 ... premium industrial buildings it is developing at Conejo ... California , to Atara Biotherapeutics, Inc. ... patients with severe and life-threatening diseases that have ... focus on allogeneic T-cell therapies for cancer, autoimmune ...
Breaking Medicine Technology: